Shifting Treatment Paradigms in Non-Hodgkin Lymphomas

This symposium took place on 22nd June 2017, as part of the 22nd Congress of the (EHA) in Madrid, Spain

Chairperson: Dolores Caballero1
Speakers: Umberto Vitolo,2 Martin Dreyling,3 Roch Houot4

1. Department of Haematology, University Hospital Salamanca, Salamanca, Spain
2. University Hospital “Città della Salute e della Scienza di Torino”, Turin, Italy
3. Medizinische Klinik III, LMU München, Munich, Germany
4. Department of Haematology, Rennes University Hospital, Rennes, France

Disclosure: Prof Caballero has served as a member of advisory boards and participated in educational activities for Bristol-Myers Squibb, Celgene, Janssen, Kite, Nordic, and Roche. Prof Vitolo has received research grants and served as principal investigator in studies sponsored by Celgene and Roche; he received sponsorship for speaking engagements at conferences and educational activities from Celgene, Gilead, Janssen, Roche, and Takeda and participated in scientific advisory boards and educational activities sponsored by Celgene, Janssen, and Roche. Prof Dreyling’s institution has received research grants from Celgene, Janssen, Mundipharma, and Roche. Prof Dreyling has received speaker’s honoraria from Bayer, Celgene, Gilead, Janssen, and Roche, and served as a member of scientific advisory boards sponsored by Bayer, Celgene, Gilead, Janssen, Mundipharma, Roche, and Sandoz. Prof Houot has received honoraria from Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Roche, and served as a consultant or advisor for Bristol-Myers Squibb and Tusk.
Acknowledgements: Writing assistance was provided by Nicole Rossides, ApotheCom, London, UK.
Support: The publication of this article was funded by Celgene. The views and opinions expressed are those of the authors and not necessarily Celgene.
Citation: EMJ Hematol. 2017;5[1]:35-43.

Meeting Summary

Despite significant therapeutic advances in the treatment of patients with non-Hodgkin lymphoma (NHL), a significant proportion experience relapse or progression following standard immunochemotherapy (ICT). The introduction of novel targeted immunotherapy agents has potentially ushered in a new era in the management of NHL. Emerging approaches to treatment, including chemo-free regimens, targeted therapies, and immunotherapy for follicular lymphoma (FL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphomas (DLBCL), have become increasingly important. Furthermore, genomic tools and biomarkers support subtyping of lymphomas and contribute greatly to identifying patients likely to respond to therapy and predict treatment outcome, thus offering a subset-specific precision medicine approach to managing NHL to both prevent and treat relapse. The latest development in the management of NHL is the use of checkpoint inhibitors to prevent cell–cell communication and tumour growth. Despite limited evidence to date, checkpoint inhibitors in combination with existing ICT may fundamentally shift the NHL treatment algorithm towards personalised immunotherapy.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 305KB)

Comments are closed.